Platelet Function in Uraemia

References

• Remuzzi G. Bleeding in renal failure. Lancet 1988; 1: 1205–1208
   PubMed Web of Science ®Google Scholar
• del Greco F, Soper W S, Krumlovsky F A, Levin M L, Baske R. Thrombosis of vascular access for haemodialysis. Haemostasis and the Kidney, G Remuzzi, E C Rossi. Butterworths, London 1989; 303–308
   Google Scholar
• Ibels L S, Stewart J H, Mahony J F, Neale F C, Sheil A G R. Occlusive arterial disease in uraemic and haemodialysis patients and renal transplant recipients. Quart J Med 1977; 46: 197–214
   PubMedGoogle Scholar
• Gotti E, Remuzzi G. Uraemic bleeding: clinical presentation and management. Haemostasis and the Kidney, G Remuzzi, E C Rossi. Butterworths, London 1989; 131–144
   Google Scholar
• Riesman D. Haemorrhage in the course of Bright's disease with especial reference to the occurrence of haemorrhagic diathesis of nephrotic origin. Amer J Med Sci 1907; 134: 709–716
   Google Scholar
• Kuhlback B. Bleeding tendency in chronic renal failure. Acta Med Scand 1957; 157: 173–177
   PubMedGoogle Scholar
• Lewis J, Zucker M, Ferguson J. Bleeding tendency in uremia. Blood 1956; 11: 1073–1076
   PubMedGoogle Scholar
• Rath C E, Maillard J A, Schreiner G E. Bleeding tendency in uremia. N Engl J Med 1957; 257: 808–810
   PubMed Web of Science ®Google Scholar
• Cheney K, Bonnin J A. Haemorrhage, platelet dysfunction and other coagulation defects in uraemia. Br J Haematol 1962; 8: 215–222
   Google Scholar
• Steiner R W, Coggins C, Carvalho A C A. Bleeding time in uremia: a useful test to assess clinical bleeding. Am J Hematol 1979; 7: 107–117
   PubMed Web of Science ®Google Scholar
• Lindsay R M, Moorthy A V, Koens F, Linton A L. Platelet function in dialyzed and non-dialyzed patients with chronic renal failure. Clin Nephrol 1975; 4: 52–57
   PubMedGoogle Scholar
• Eknoyan G, Wacksman S J, Glueck H I, Will J J. Platelet function in renal failure. N Engl J Med 1969; 280: 677–681
   PubMed Web of Science ®Google Scholar
• Gafter U, Bessler H, Malachi T, Zevin D, Djaldetti M, Levi J. Platelet count and thrombopoietic activity in patients with chronic renal failure. Nephron 1987; 45: 207–210
   PubMed Web of Science ®Google Scholar
• Castaldi P A, Rozenberg M C, Stewart J H. The bleeding disorder of uraemia. A qualitative platelet defect. Lancet 1966; ii: 66–69
   Google Scholar
• Evans E P, Branch R A, Bloom A L. A clinical and experimental study of platelet function in chronic renal failure. J Clin Pathol 1972; 25: 745–753
   Google Scholar
• Di Minno G, Martinez J, McKean M, De La Rosa J, Burke J F, Murphy S. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med 1985; 79: 552–559
   PubMed Web of Science ®Google Scholar
• Di Minno G, Cerbone A, Usberti M, et al. Platelet dysfunction in uremia. Correction by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen. J Lab Clin Med 1986; 108: 246–252
   Google Scholar
• Lindsay R M, Friesen M, Aronstam A, Andrus F, Clark W F, Linton A L. Improvement of platelet function by increased frequency of haemodialysis. Clin Nephrol 1978; 10: 67–70
   PubMed Web of Science ®Google Scholar
• Lindsay R M, Friesen M, Koens F, Linton A L, Oreopoulos D, De Veber G. Platelet function in patients on long term peritoneal dialysis. Clin Nephrol 1976; 6: 335–339
   PubMedGoogle Scholar
• Rabiner S F, Molinas F. The role of phenol and phenolic acid on the thrombocytopathy and defective platelet aggregation of patients with renal failure. Am J Med 1970; 49: 346–351
   PubMed Web of Science ®Google Scholar
• Horowitz H I, Stein I M, Cohen B D, White J G. Further studies on the platelet-inhibiting effect of guanidinosuccinic acid and its role in uremic bleeding. Am J Med 1970; 49: 336–340
   PubMed Web of Science ®Google Scholar
• Horowitz H I. Uremic toxins and platelet function. Arch Int Med 1970; 126: 823–826
   PubMedGoogle Scholar
• Bazilinski N, Shaykh M, Dunea G, et al. Inhibition of platelet function by uremic middle molecules. Nephron 1985; 40: 423–428
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Livio M, Marchiaro G, Mecca G, De Gaetano G. Bleeding in renal failure: altered platelet function in chronic uraemia only partially corrected by haemodialysis. Nephron 1978; 22: 347–353
   PubMed Web of Science ®Google Scholar
• Nenci G G, Berrettini M, Agnelli G, Parise P, Buoncristiani U, Ballatori E. Effect of peritoneal dialysis, haemodialysis and kidney transplantation on blood platelet function. Nephron 1979; 23: 287–292
   Google Scholar
• Jorgensen K A, Ingeberg S. Platelets and platelet function in patients with chronic uremia on maintenance hemodialysis. Nephron 1979; 23: 233–236
   Google Scholar
• Viener A, Aviram M, Better O S, Brook J G. Enhanced in vitro platelet aggregation in haemodialysis patients. Nephron 1986; 43: 139–143
   Google Scholar
• Remuzzi G, Benigni A, Dodesini P, et al. Platelet function in patients on maintainence hemodialysis: depressed or enhanced?. Clin Nephrol 1982; 17: 60–63
   PubMedGoogle Scholar
• Cameron J S. Platelets in glomerular disease. Ann Rev Med 1984; 35: 175–180
   Google Scholar
• Colwell J A, Halushka P V. Platelet function in diabetes mellitus. Br J Haematol 1980; 44: 521–526
   Google Scholar
• Jackson C A, Greaves M, Patterson A D, Brown C B, Preston F E. Relationship between platelet aggregation, thromboxane synthesis and albumin concentration in nephrotic syndrome. Br J Haematol 1982; 52: 69–77
   PubMed Web of Science ®Google Scholar
• Bennett A, Cameron J S. Platelet hyperaggregability in the nephrotic syndrome which is not dependant on arachidonic acid metabolism or on plasma albumin concentration. Clin Nephrol 1987; 27: 182–188
   PubMed Web of Science ®Google Scholar
• Turney J H, Williams L C, Fewell M R, Parsons V, Weston M J. Platelet protection and heparin sparing with prostacyclin during regular dialysis therapy. Lancet 1980; ii: 219–222
   Google Scholar
• Salzman E W, Rosenberg R D, Smith M H, Lindon J N, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64–73
   PubMed Web of Science ®Google Scholar
• Aviram M, Brook J G. Platelet interaction with high and low density lipoproteins. Atherosclerosis 1983; 46: 259–265
   PubMed Web of Science ®Google Scholar
• Eknoyan G, Brown C H. Biochemical abnormalities of platelets in renal failure. Evidence for decreased platelet serotonin, adenosine diphosphate and Mg-dependent adenosine triphosphatase. Am J Nephrol 1981; 1: 17–23
   PubMed Web of Science ®Google Scholar
• Kyrie P A, Stockenhuber F, Brenner B, et al. Evidence for an increased generation of prostacyclin in the microvasculature and an impairment of the platelet α granule release in chronic renal failure. Thromb Haemostas 1988; 60: 205–208
   Google Scholar
• Tison P, Cernacek P, Silvanova E, Dzurik R. Uraemic toxins and blood platelet carbohydrate metabolism. Nephron 1981; 28: 192–195
   Google Scholar
• Vlacoyannis J, Schoeppe W. Adenylate cyclase activity and cAMP content of human platelets in uraemia. Eur. J Clin Invest 1982; 12: 379–381
   Google Scholar
• Jacobsson B, Ransnas L, Nyberg G, Bergh C-H, Magnusson Y, Hjalmarzon A. Abnormality of adenylate cyclase regulation in human platelet membranes in renal insufficiency. Eur. J Clin Invest 1985; 15: 75–81
   Google Scholar
• Massry S G, Goldstein D A. The search for uremic toxin(s) “X”. “X” = PTH. Clin Nephrol 1979; 11: 181–189
   PubMed Web of Science ®Google Scholar
• Benigni A, Livio M, Dodesini P, et al. Inhibition of human platelet aggregation by parathyroid hormone. Is cyclic AMP implicated?. Am J Nephrol 1985; 5: 243–247
   Google Scholar
• Vigano G, Gotti E, Comberti E, Giangrande A, Trevisan R, Remuzzi G. Hyperparathyroidism does not influence the abnormal primary haemostasis in patients with chronic renal failure. Nephrol Dial Transplant 1989; 4: 971–974
   Google Scholar
• Docci D, Turci F, Delvecchio C, Gollini C, Baldrati L, Pistocchi E. Lack of evidence for the role of secondary hyperparathyroidism in the pathogenesis of uremic thrombocytopathy. Nephron 1986; 43: 28–32
   Google Scholar
• Leithner C, Kovarik J, Sinzinger H, Woloszczuk W. Parathyroid hormone does not inhibit platelet aggregation. Lancet 1984; i: 367–368
   Google Scholar
• Gura V, Creter D, Levi J. Elevated thrombocyte calcium content in uraemia and its correction by lalpha(OH) vitamin D treatment. Nephron 1982; 30: 237–239
   PubMedGoogle Scholar
• Ware J A, Clark B A, Smith M, Salzman E W. Abnormalities of cytoplasmic Ca2+ in platelets from patients with uremia. Blood 1989; 73: 172–176
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Marchesi D, Livio M, et al. Altered platelet and vascular prostaglandin generation in patients with renal failure and prolonged bleeding times. Thromb Res 1978; 13: 1007–1015
   PubMed Web of Science ®Google Scholar
• Fernandez F, Goudable C, Sie P, et al. Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions. Br J Haematol 1985; 59: 139–148
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Benigni A, Dodesini P, et al. Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect. J Clin Invest 1983; 71: 762–768
   PubMed Web of Science ®Google Scholar
• Smith M C, Dunn M J. Impaired platelet thromboxane production in renal failure. Nephron 1981; 29: 133–137
   Google Scholar
• Sinzinger H, Leithner C. Eicosanoids of platelets and vascular wall in chronic renal insufficiency. Am J Nephrol 1987; 7: 212–220
   Google Scholar
• Winter M, Frampton G, Bennett A, Machin S J, Cameron J S. Synthesis of thromboxane B2 in uraemia and the effects of dialysis. Thromb Res 1983; 30: 265–272
   Google Scholar
• Bloom A, Greaves M, Preston F E, Brown C B. Evidence against a platelet cyclooxygenase defect in uraemic subjects on chronic haemodialysis. Br J Haematol 1986; 62: 143–149
   PubMed Web of Science ®Google Scholar
• Andrassy K, Koderisch J, Lamminger C. Defective platelet membrane receptors as a cause of uraemic bleeding. Blut 1988; 53: 243–243, Abstract
   Google Scholar
• Castillo R, Lozano T, Escolar G, Revert L, Lopez J, Ordinas A. Defective platelet adhesion on vessel subendothelium in uremic patients. Blood 1986; 68: 337–342
   Google Scholar
• Escolar G, Cases A, Bastida E, et al. Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb-IIIa. Blood 1990; 76: 1336–1340
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Marchesi D, Cavenaghi A E, et al. Bleeding in renal failure: a possible role of vascular prostacyclin (PG12). Clin Nephrol 1979; 12: 127–131
   Google Scholar
• Defreyn G, Vergara Dauden M, Machin S J, Vermylen J. A plasma factor in uraemia which stimulates prostacyclin release from cultured endothelial cells. Thromb Res 1980; 19: 695–699
   PubMedGoogle Scholar
• Zoja C, Vigano G, Bergamelli A, Benighni A, de Gaetano G, Remuzzi G. Prolonted bleeding time and increased vacular prostacyclin in rats with chronic renal failure: effects of conjugated estrogens. J Lab Clin Med 1988; 112: 380–386
   Google Scholar
• Janson P A, Jubelirer S J, Weinstein M J, Deykin D. Treatment of the bleeding tendency in uraemia with cryoprecipitate. N Engl J Med 1980; 303: 1318–1322
   PubMed Web of Science ®Google Scholar
• Mannucci P M, Remuzzi G, Pusineri F, et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uraemia. N Engl J Med 1983; 308: 8–12
   PubMed Web of Science ®Google Scholar
• Mannucci P M. Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 1988; 72: 1449–1455
   PubMed Web of Science ®Google Scholar
• Escolar G, Cases A, Monteagudo J, et al. Uremic plasma after infusion of desmopressin (DDAVP) improves the interaction of normal platelets with vessel subendothelium. J Lab Clin Med 1989; 114: 36–42
   Google Scholar
• Livio M, Mannucci P M, Vigano G, et al. Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med 1986; 315: 731–735
   PubMed Web of Science ®Google Scholar
• Zoja C, Vigano G, Corna D, Salmona M, Remuzzi G, Garattini S. Oral zeranol shortens the prolonged bleeding time of uremic rats. Kidney Int 1990; 38: 96–100
   Google Scholar
• Kazatchkine M, Sultan Y, Caen J P, Bariety J. Bleeding in renal failure: a possible cause. Br Med J 1976; 2: 612–615
   Google Scholar
• Ruggeri Z M, Ponticelli C, Mannucci P M. Factor VIII and chronic renal failure. Br Med J 1977; 1: 1085–1085
   Google Scholar
• Warrell R P, Hultin M B, Coller B S. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in renal failure. Am J Med 1979; 66: 226–228
   PubMed Web of Science ®Google Scholar
• Turney J H, Woods H F, Fewell M R, Weston M J. Factor VIII complex in uraemia and effects of haemodialysis. Br Med J 1981; 282: 1653–1656
   PubMed Web of Science ®Google Scholar
• Wegmuller E, Gruninger U, Furlan M, Beck E A, Hodler J, Reubi F C. Factor VIII activity in chronic renal disease. Nephron 1981; 28: 157–162
   Google Scholar
• Howard M A, Whitworth J A, Hendrix L E, Thomas K B, Firkin B G. Abnormal factor VIII in chronic renal failure. Med J Australia 1979; 1: 148–151
   Google Scholar
• Weinstein M J, Chute L E, Schmitt G W, et al. Abnormal factor VIII coagulant antigen in patients with renal dysfunction and in those with disseminated intravascular coagulation. J Clin Invest 1985; 76: 1406–1411
   Google Scholar
• Editorial. Factor VIII related antigen and vasculitis. Lancet 1988; i: 1203–1204
   Google Scholar
• Milani L, Merkel C, Canel F, Gasparotto M L, Gatta A. Relationship between plasma levels of factor VIII related antigen and reticulo-endothelial function in chronic uraemia. Clin Nephrol 1983; 20: 235–238
   Google Scholar
• Pottinger B E, Read R C, Palcolog E M, Higgins P G, Pearson J D. von Willebrand factor is an acute phase reactant in man. Thromb Res 1989; 53: 387–394
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Bertani T, Mecca G, Donati M B, De Gaetano G. Factor VIII related protein on vascular intima of patients with chronic renal failure and prolonged bleeding times. Br Med J 1978; 1: 70–72
   Google Scholar
• Gralnick H R, McKeown L P, Williams S B, Shafer B C, Pierce L. Plasma and platelet von Willebrand factor defects in uremia. Am J Med 1988; 85: 806–810
   PubMed Web of Science ®Google Scholar
• Gralnick H R, Williams S B, Morisato D K. Effect of the multimeric structure of the factor VIII/von Willebrand factor protein on binding to platelets. Blood 1981; 58: 387–397
   PubMed Web of Science ®Google Scholar
• Winter M, Seghatchian M J, Cameron J S. An abnormal factor VIII molecule in uraemia?. Lancet 1983; i: 1112
   Google Scholar
• Cases A, Monteagudo J, Escolar G, et al. Normal binding of native and asiolo-von Willebrand factor to uraemic platelets. Nephrol Dial Transplant 1988; 3: 531–531, Abstract
   Google Scholar
• Aznar-Salatti J, Hernandez R, Anton P, Cases A, Escolar G, Ordinas A. Serum obtained from uremic patients modifies the reactivity towards platelets of extracellular matrices produced by endothelial cells. VIth International Symposium on the Biology of Vascular Cells 1990; 1: 57–57, Abstract
   Google Scholar
• Hellem A J, Borchgrevink C F, Ames S B. The role of red cells in haemostasis: the relation between haematocrit, bleeding time and platelet adhesiveness. Br J Haematol 1961; 7: 42–50
   PubMed Web of Science ®Google Scholar
• Gaarder A, Jonsen J, Laland S, Hellem A, Owren P A. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961; 192: 531–532
   PubMed Web of Science ®Google Scholar
• Willems C, Stel H V, van Aken W G, van Mourik J A. Binding and inactivation of prostacyclin (PG12) by human erythrocytes. Br J Haematol 1983; 54: 43–52
   Google Scholar
• Turitto V T, Weiss H J. Red blood cells: their dual role in thrombus formation. Science 1980; 207: 541–543
   PubMed Web of Science ®Google Scholar
• Livio M, Gotti E, Marchesi D, Mecca G, Remuzzi G, De Gaetano G. Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions. Lancet 1982; 2: 1013–1015
   PubMed Web of Science ®Google Scholar
• Gordge M P, Faint R W, Rylance P B, Neild G H. Platelet function and the bleeding time in progressive renal failure. Thromb Haemostas 1988; 60: 83–87
   PubMedGoogle Scholar
• Gordge M P, Dodd N J, Rylance P B, Weston M J. An assessment of whole blood impedance aggregometry using blood from normal subjects and haemodialysis patients. Thromb Res 1984; 36: 17–27
   PubMed Web of Science ®Google Scholar
• Gordge M P, Leaker B R, Patel A, Oviasu E, Cameron J S, Neild G H. Recombinant human erythropoetin corrects uraemic bleeding without causing intravascular haemostatic activation. Thromb Res 1990; 57: 171–182
   Google Scholar
• Moia M, Mannucci P M, Vizzotto L, Casati S, Cattaneo M, Ponticelli C. Improvement in the haernostatic defect of uraemia after treatment with recombinant human erythropoeitin. Lancet 1987; ii: 1227–1229
   Google Scholar
• van Geet C, Hauglustaine D, Verresen L, Vanrusselt M, Vermylen J. Haemostatic effects of recombinant human erythropoeitin in chronic haemodialysis patients. Thromb Haemostas 1989; 61: 117–121
   Google Scholar
• Andrassy K, Ritz E. Uremia as a cause of bleeding. Am J Nephrol 1985; 5: 313–319
   PubMed Web of Science ®Google Scholar
• Livio M, Benigni A, Vigano G, Mecca G, Remuzzi G. Moderate doses of aspirin and risk of bleeding in renal failure. Lancet 1986; i: 414–416
   Google Scholar
• Gaspari F, Vigano G, Orisio S, Bonati M, Livio M, Remuzzi G. Aspirin prolongs bleeding time in ureamia by a mechanism distinct from platelet cyclooxygenase inhibition. J Clin Invest 1987; 79: 1788–1797
   PubMed Web of Science ®Google Scholar
• Lindner A, Charra B, Sherrard D J, Scribner B H. Accelerated atherosclerosis in prolonged maintenance hemodialysis. New Engl J Med 1974; 290: 697–701
   PubMed Web of Science ®Google Scholar
• Brunner F P, Brynger H, Chantler C, et al. Combined report on regular dialysis and transplantation in Europe. Proc Eur Dial Transpl Assoc 1978; 16: 28–29
   Google Scholar
• Broyer M, Brunner F P, Brynger H, et al. Demography of dialysis and transplantation in Europe, 1984. Nephrol Dial Transplant 1986; 1: 1–8
   PubMedGoogle Scholar
• Degoulet P, Legrain M, Reach I, et al. Mortality risk factors in patients treated by chronic hemodialysis. Nephron 1982; 31: 103–110
   PubMed Web of Science ®Google Scholar
• Ritz E, Bommer J, Augustin J. Atherogenesis in uremia. Contr Nephrol 1984; 41: 337–341
   Google Scholar
• Lindsay R M, Prentice C R M, Davidson J F, Burton J A, McNicol G P. Haemostatic changes during dialysis associated with thrombus formation on dialysis membranes. Br Med J 1972; 4: 454–458
   PubMed Web of Science ®Google Scholar
• Sultan Y, London G M, Goldfarb B, Toulon P, Marchais S J. Activation of platelets, coagulation and fibrinolysis in patients on long-term haemodialysis: influence of cuprophan and polyacrylonitrile membranes. Nephrol Dial Transplant 1990; 5: 362–368
   PubMed Web of Science ®Google Scholar
• Kristensen S D, Knudsen F, Nielsen A H, Ring T. Decreased platelet sensitivity to prostacyclin (epoprostenol) during hemodialysis. Clin Nephrol 1984; 21: 230–234
   PubMed Web of Science ®Google Scholar
• Wardle E N, Piercy D A. Studies of contact activation of blood in haemodialysis. J Clin Pathol 1972; 25: 1045–1049
   PubMedGoogle Scholar
• Speiser W, Wojta J, Korninger C, Kirchheimer J C, Zazgornik J, Binder B R. Enhanced fibrinolysis caused by tissue plasminogen activator release in hemodialysis. Kidney Int 1987; 32: 280–283
   Google Scholar
• Chenoweth D E, Cheung A K, Henderson L W. Anaphylotoxin formation during hemodialysis: effects of different dialyzer membranes. Kidney Int 1983; 24: 764–769
   PubMed Web of Science ®Google Scholar
• Rylance P B, Gordge M P, Ireland H, Lane D A, Weston M J. Haemodialysis with prostacyclin (epoprostenol) alone. Proc Eur Dial Transpl Assoc 1984; 21: 281–286
   Google Scholar
• Schmitt G W, Moake J L, Rudy C K, Vicks S L, Hamburger R J. Alterations in hemostatic parameters during hemodialysis with dialyzers of different membrane composition and flow design. Am J Med 1987; 83: 411–418
   Google Scholar
• Notohamiprodjo M, Andrassy K, Bommer J, Ritz E. Dialysis membranes and coagulation system. Blood Purification 1986; 4: 130–141
   Google Scholar
• Lindsay R M, Prentice C R M, Ferguson D, Burton J A, McNicol G P. Reduction of thrombus formation on dialyser membranes by aspirin and RA 233. Lancet 1972; ii: 1287–1290
   Google Scholar
• Woods H F, Ash G, Parsons V, Weston M J. Reduction of dialyzer fibrin deposition with sulphinpyrazone. Clin Nephrol 1979; 12: 122–126
   Google Scholar
• Dodd N J, Gordge M P, Weston M J. Use of a thromboxane synthetase inhibitor, Dazoxiben, during haemodialysis. Br J Clin Pharmacol 1983; 15: 67S–70S
   Google Scholar
• Zusman R M, Rubin R H, Cato A E, Cocchetto D M, Crow J W. Tolkoff-Rubin N. Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. N Engl J Med 1981; 304: 934–939
   PubMed Web of Science ®Google Scholar
• Casati S, Moia M, Graziani G, et al. Hemodialysis withou anticoagulants: efficiency and hemostatic aspects. Clin Nephrol 1984; 21: 102–105
   Google Scholar
• Ireland H, Lane D A, Curtis J R. Objective assessment of heparin requirements for haemodialysis in humans. J Lab Clin Med 1984; 103: 643–652
   PubMed Web of Science ®Google Scholar
• Radomski M W, Palmer R M J, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Comm 1987; 148: 1482–1489
   PubMed Web of Science ®Google Scholar